Skip to main content

Advertisement

SpringerLink
Log in

Advances in Juvenile Spondyloarthritis

  • Spondyloarthritis (M Khan and N Akkoc, Section Editors)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose

To provide an overview of recent studies on pathogenesis, diagnosis, and management of juvenile spondyloarthritis (JSpA).

Recent Findings

Recent studies show differences in gut microbiome in patients with JSpA in comparison to healthy controls. There is increased recognition of the impact of the innate immune system on disease pathology. Normative reference on MRI of sacroiliac (SI) joints in children is now available. However, there is significant variability in interpretation of MRI of SI joints in children and a need for standardization. NSAIDs, physical therapy, and Tumor Necrosis Factor Inhibitors (TNFi) remain the mainstay of management for patients with JIA who have polyarthritis, sacroiliitis, and/or enthesitis as per recent ACR guidelines. Newer therapeutic options beyond TNFi are needed to manage patients who fail TNFi.

Summary

This review highlights some of the recent advances in our knowledge of JSpA pathophysiology, diagnosis, and treatment. It also identifies areas in need of further research and standardization to improve our understanding and outcomes in JSpA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature reviews Rheumatology. 2021.

  2. Weiß A, Minden K, Listing J, Foeldvari I, Sieper J, Rudwaleit M. Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC. RMD open. 2017;3(1):e000366.

    Article  Google Scholar 

  3. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. The Journal of rheumatology. 2004;31(2):390–2.

    Google Scholar 

  4. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and rheumatism. 1984;27(4):361–8.

    Article  Google Scholar 

  5. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis and rheumatism. 1991;34(10):1218–27.

    Article  CAS  Google Scholar 

  6. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic. 1990;57(2):85–9.

    CAS  Google Scholar 

  7. Stoll ML, Bhore R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. The Journal of rheumatology. 2010;37(11):2402–8.

    Article  PubMed Central  Google Scholar 

  8. Burgos-Vargas R, Pacheco-Tena C, Vázquez-Mellado J. A short-term follow-up of enthesitis and arthritis in the active phase of juvenile onset spondyloarthropathies. Clinical and experimental rheumatology. 2002;20(5):727–31.

    CAS  Google Scholar 

  9. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Current opinion in rheumatology. 2011;23(5):437–43.

    Article  Google Scholar 

  10. Ravelli A, Consolaro A, Schiappapietra B, Martini A. The conundrum of juvenile psoriatic arthritis. Clinical and experimental rheumatology. 2015;33(5 Suppl 93):S40–3.

    Google Scholar 

  11. Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis and rheumatism. 2011;63(9):2809–18.

    Article  Google Scholar 

  12. Modesto C, Antón J, Rodriguez B, Bou R, Arnal C, Ros J, et al. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scandinavian journal of rheumatology. 2010;39(6):472–9.

    Article  CAS  Google Scholar 

  13. Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chédeville G, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis care & research. 2010;62(4):527–36.

    Article  Google Scholar 

  14. Kunjir V, Venugopalan A, Chopra A. Profile of Indian patients with juvenile onset chronic inflammatory joint disease using the ILAR classification criteria for JIA: a community-based cohort study. The Journal of rheumatology. 2010;37(8):1756–62.

    Article  Google Scholar 

  15. Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2012;39(12):2341–51.

    Article  Google Scholar 

  16. Taxter AJ, Wileyto EP, Behrens EM, Weiss PF. Patient-reported Outcomes across Categories of Juvenile Idiopathic Arthritis. The Journal of rheumatology. 2015;42(10):1914–21.

    Article  CAS  Google Scholar 

  17. Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. The Journal of rheumatology. 2011;38(12):2675–81.

    Article  CAS  Google Scholar 

  18. Brunner HI, Schanberg LE, Kimura Y, Dennos A, Co DO, Colbert RA, et al. New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. Arthritis & Rheumatology (Hoboken, NJ). 2020;72(11):1945–51.

    Article  Google Scholar 

  19. Rizzo A, Guggino G, Ferrante A, Ciccia F. Role of subclinical gut inflammation in the pathogenesis of spondyloarthritis. Frontiers in medicine. 2018;5:63.

    Article  Google Scholar 

  20. Stoll ML, Punaro M, Patel AS. Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis. The Journal of rheumatology. 2011;38(10):2274–5.

    Article  Google Scholar 

  21. Cardoneanu A, Mihai C, Rezus E, Burlui A, Popa I, Cijevschi PC. Gut microbiota changes in inflammatory bowel diseases and ankylosing spondilytis. J Gastrointestin Liver Dis. 2021.

  22. Tito RY, Cypers H, Joossens M, Varkas G, Van Praet L, Glorieus E, et al. Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthritis. Arthritis & rheumatology (Hoboken, NJ). 2017;69(1):114–21.

    Article  CAS  Google Scholar 

  23. Campos-Perez W, Martinez-Lopez E. Effects of short chain fatty acids on metabolic and inflammatory processes in human health. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;158900.

  24. Stoll ML, Weiss PF, Weiss JE, Nigrovic PA, Edelheit BS, Bridges SL Jr, et al. Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis research & therapy. 2018;20(1):14.

    Article  CAS  Google Scholar 

  25. Gill T, Asquith M, Brooks SR, Rosenbaum JT, Colbert RA. Effects of HLA-B27 on Gut Microbiota in Experimental Spondyloarthritis Implicate an Ecological Model of Dysbiosis. Arthritis Rheumatol. 2018;70(4):555–65.

    Article  CAS  Google Scholar 

  26. Stoll ML, Duck LW, Chang MH, Colbert RA, Nigrovic PA, Thompson SD, et al. Identification of Prevotella Oralis as a possible target antigen in children with Enthesitis related arthritis. Clin Immunol. 2020;216:108463.

    Article  CAS  Google Scholar 

  27. Lai CY, Sung J, Cheng F, Tang W, Wong SH, Chan PKS, et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther. 2019;49(4):354–63.

    Article  Google Scholar 

  28. Ghantous N, Heshin-Bekenstein M, Dequattro K, Lakovsky Y, Hendel AM, Rappoport N, et al. Do geography and ethnicity play a role in juvenile Spondyloarthritis? A multi-center binational retrospective study. Pediatr Rheumatol Online J. 2021;19(1):4.

    Article  Google Scholar 

  29. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature genetics. 2011;43(8):761–7.

    Article  CAS  Google Scholar 

  30. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. American journal of human genetics. 2007;80(2):273–90.

    Article  CAS  Google Scholar 

  31. Hinks A, Martin P, Flynn E, Eyre S, Packham J, Barton A, et al. Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. Arthritis research & therapy. 2011;13(1):R12.

    Article  CAS  Google Scholar 

  32. Wang Z, Han Y, Zhang Z, Jia C, Zhao Q, Song W, et al. Identification of genes and signaling pathways associated with the pathogenesis of juvenile spondyloarthritis. Mol Med Rep. 2018;18(2):1263–70.

    CAS  PubMed Central  Google Scholar 

  33. Kasper M, Walscheid K, Laffer B, Bauer D, Busch M, Loser K, et al. Phenotype of Innate Immune Cells in Uveitis Associated with Axial Spondyloarthritis- and Juvenile Idiopathic Arthritis-associated Uveitis. Ocul Immunol Inflamm. 2020:1–10.

  34. Inciarte-Mundo J, Ramirez J, Hernandez MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Res Ther. 2018;20(1):275.

    Article  CAS  PubMed Central  Google Scholar 

  35. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal. 2013;18(17):2352–63.

    Article  CAS  PubMed Central  Google Scholar 

  36. Baeten D, Demetter P, Cuvelier CA, Kruithof E, Van Damme N, De Vos M, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol. 2002;196(3):343–50.

    Article  CAS  Google Scholar 

  37. Bhattacharya S, Misra R, Aggarwal A. Patients with enthesitis related arthritis show similar monocyte function pattern as seen in adult axial spondyloarthropathy. Pediatr Rheumatol Online J. 2020;18(1):6.

    Article  PubMed Central  Google Scholar 

  38. Reinhardt A, Prinz I. Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing gammadelta T Cells, alphabeta T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis. Front Immunol. 2018;9:885.

    Article  PubMed Central  CAS  Google Scholar 

  39. Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol. 2014;57(1):44–51.

    Article  CAS  Google Scholar 

  40. DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis and rheumatism. 2009;60(9):2633–43.

    Article  CAS  Google Scholar 

  41. Flores RR, Carbo L, Kim E, Van Meter M, De Padilla CML, Zhao J, et al. Adenoviral gene transfer of a single-chain IL-23 induces psoriatic arthritis-like symptoms in NOD mice. FASEB J. 2019;33(8):9505–15.

    Article  CAS  PubMed Central  Google Scholar 

  42. Venken K, Jacques P, Mortier C, Labadia ME, Decruy T, Coudenys J, et al. RORgammat inhibition selectively targets IL-17 producing iNKT and gammadelta-T cells enriched in Spondyloarthritis patients. Nat Commun. 2019;10(1):9.

    Article  CAS  Google Scholar 

  43. Chen S, Paveley R, Kraal L, Sritharan L, Stevens E, Dedi N, et al. Selective targeting of PI3Kdelta suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases. J Autoimmun. 2020;111:102435.

    Article  CAS  Google Scholar 

  44. Weiss PF, Chauvin NA, Roth J. Imaging in Juvenile Spondyloarthritis. Current rheumatology reports. 2016;18(12):75.

    Article  Google Scholar 

  45. Jaremko JL, Liu L, Winn NJ, Ellsworth JE, Lambert RG. Diagnostic utility of magnetic resonance imaging and radiography in juvenile spondyloarthritis: evaluation of the sacroiliac joints in controls and affected subjects. The Journal of rheumatology. 2014;41(5):963–70.

    Article  Google Scholar 

  46. Weiss PF, Xiao R, Brandon TG, Biko DM, Maksymowych WP, Lambert RG, et al. Radiographs in screening for sacroiliitis in children: what is the value? Arthritis research & therapy. 2018;20(1):141.

    Article  CAS  Google Scholar 

  47. Chauvin NA, Xiao R, Brandon TG, Biko DM, Francavilla M, Khrichenko D, et al. MRI of the Sacroiliac Joint in Healthy Children. AJR Am J Roentgenol. 2019:1–7.

  48. Weiss PF, Brandon TG, Bohnsack J. Heshin-Bekenstein M. Jaremko JL, et al. Variability in magnetic resonance imaging interpretation of the pediatric sacroiliac joint. Arthritis care & research: Francavilla ML; 2020.

    Google Scholar 

  49. Otobo TM, Conaghan PG, Maksymowych WP, van der Heijde D, Weiss P, Sudol-Szopinska I, et al. Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ). The Journal of rheumatology. 2019;46(9):1192–7.

    Article  Google Scholar 

  50. Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Williams M, Stone M, et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis and rheumatism. 2005;53(5):703–9.

    Article  Google Scholar 

  51. Maksymowych WP, Wichuk S, Chiowchanwisawakit P, Lambert RG, Pedersen SJ. Development and preliminary validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging sacroiliac joint structural score. The Journal of rheumatology. 2015;42(1):79–86.

    Article  Google Scholar 

  52. Panwar J, Tse SML, Lim L, Tolend MA, Radhakrishnan S, Salman M, et al. Spondyloarthritis Research Consortium of Canada Scoring System for Sacroiliitis in Juvenile Spondyloarthritis/Enthesitis-related Arthritis: A Reliability, Validity, and Responsiveness Study. The Journal of rheumatology. 2019;46(6):636–44.

    Article  Google Scholar 

  53. Weiss PF, Maksymowych WP, Xiao R, Biko DM, Francavilla ML, Lambert RG, et al. Spondyloarthritis Research Consortium of Canada sacroiliac joint inflammation and structural scores: change score reliability and recalibration utility in children. Arthritis research & therapy. 2020;22(1):58.

    Article  Google Scholar 

  54. Panwar J, Patel H, Tolend M, Akikusa J, Herregods N, Highmore K, et al. Toward Developing a Semiquantitative Whole Body-MRI Scoring for Juvenile Idiopathic Arthritis: Critical Appraisal of the State of the Art, Challenges, and Opportunities. Academic radiology. 2021;28(2):271–86.

    Article  Google Scholar 

  55. Bridges JM, Stoll ML. Treatment of Juvenile Spondyloarthritis: Where We Stand. Paediatr Drugs. 2020;22(6):603–15.

    Article  Google Scholar 

  56. Weiss PF, Fuhlbrigge RC, von Scheven E, Lovell DJ, Colbert RA, Brunner HI. Children with enthesitis-related arthritis could benefit from treatments targeted for adults with spondyloarthritis. Arthritis care & research. 2020.

  57. Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis & rheumatology (Hoboken, NJ). 2019;71(6):846–63.

    Article  Google Scholar 

  58. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis & rheumatology (Hoboken, NJ). 2019;71(10):1599-613.

  59. Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, et al. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis care & research. 2015;67(11):1503–12.

    Article  CAS  Google Scholar 

  60. Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, et al. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. The Journal of rheumatology. 2016;43(4):816–24.

    Article  CAS  Google Scholar 

  61. Foeldvari I, Constantin T, Vojinović J, Horneff G, Chasnyk V, Dehoorne J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis research & therapy. 2019;21(1):125.

    Article  CAS  Google Scholar 

  62. Kearsley-Fleet L, Davies R, Lunt M, Southwood TR, Hyrich KL. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford, England). 2016;55(5):840–7.

    Article  CAS  Google Scholar 

  63. Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the rheumatic diseases. 2018;77(1):21–9.

    Article  CAS  Google Scholar 

  64. Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, et al. Open-Label Phase 3 Study of Intravenous Golimumab in Patients With Polyarticular Juvenile Idiopathic Arthritis. Rheumatology (Oxford, England). 2021.

  65. Weiss PF, Xiao R, Brandon TG, Pagnini I, Wright TB, Beukelman T, et al. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. The Journal of rheumatology. 2018;45(1):107–14.

    Article  CAS  Google Scholar 

  66. Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, et al. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clinical rheumatology. 2017;36(8):1747–55.

    Article  Google Scholar 

  67. Skrabl-Baumgartner A, Erwa W, Muntean W, Jahnel J. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scandinavian journal of rheumatology. 2015;44(5):359–62.

    Article  CAS  Google Scholar 

  68. Chamlati R, Connolly B, Laxer R, Stimec J, Panwar J, Tse S, et al. Image guided sacroiliac joint corticosteroid injections in children: an 18-year single-center retrospective study. Pediatric rheumatology online journal. 2020;18(1):52.

    Article  Google Scholar 

  69. van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–51.

    Article  Google Scholar 

  70. Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2019;71(4):599–611.

    Article  CAS  PubMed Central  Google Scholar 

  71. Dougados M, Wei JC, Landewe R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176–85.

    Article  CAS  Google Scholar 

  72. Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.

    Article  CAS  Google Scholar 

  73. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700.

    Article  CAS  Google Scholar 

  74. McInnes IB, Chakravarty SD, Apaolaza I, Kafka S, Hsia EC, You Y, et al. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD open. 2019;5(2):e000990.

    Article  Google Scholar 

  75. Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the rheumatic diseases. 2018;77(9):1295–302.

    Article  CAS  Google Scholar 

  76. Mannion ML, McAllister L, Cron RQ, Stoll ML. Ustekinumab as a Therapeutic Option for Children With Refractory Enthesitis-Related Arthritis. Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases. 2016;22(5):282–4.

    Article  Google Scholar 

  77. Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatric rheumatology online journal. 2017;15(1):86.

    Article  Google Scholar 

  78. Brunner H SO, Ting T, Abud Mendoza C, Spindler A, Vyzhga Y, Marzan K, Keltsev V, Tirosh I, Imundo L, Jerath R, Kingsbury D, Sozeri B, Vora S, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, V. Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study. American College of Rheumatology Arthritis Rheumatol; 2019.

  79. Brunner H AJ, Al-Abadi E, Bohnsack J, Boteanu A, Chedeville G, Cuttica R, De La Pena W, Jung L, Kasapcopur O, Kobusinska K, Schulert G, Neiva C, Rivas-Chacon R, Cruz Rizo Rodriguez J, Vazquez-Del Mercado M, Wagner-Weiner L, Weiss J, Wouters C, Suehiro R, Posner H, Wouters A, Kanik K, Luo Z, Martini A, Lovell D, Ruperto N. Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study. American College of Rheumatology Arthritis Rheumatol; 2020.

  80. Van Mechelen M, Lories R. Spondyloarthritis on the Move: Biomechanical Benefits or Harm. Current rheumatology reports. 2020;22(8):35.

    Article  Google Scholar 

  81. Powell AP, English J. Exercise for Athletes With Inflammatory Arthritis. Curr Sports Med Rep. 2018;17(9):302–7.

    Article  Google Scholar 

  82. Houghton KM, Macdonald HM, McKay HA, Guzman J, Duffy C, Tucker L. Feasibility and safety of a 6-month exercise program to increase bone and muscle strength in children with juvenile idiopathic arthritis. Pediatric rheumatology online journal. 2018;16(1):67.

    Article  Google Scholar 

  83. Toupin April K, Stinson J, Cavallo S, Proulx L, Wells GA, Duffy CM, et al. Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis: Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2020;9(7):e12823.

    Article  Google Scholar 

  84. Morgan EM, Munro JE, Horonjeff J, Horgan B, Shea B, Feldman BM, et al. Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. The Journal of rheumatology. 2019;46(8):1006–13.

    Article  Google Scholar 

  85. Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, DeWitt EM, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis care & research. 2014;66(12):1775–82.

    Article  Google Scholar 

  86. Zanwar A, Phatak S, Aggarwal A. Prospective validation of the Juvenile Spondyloarthritis Disease Activity Index in children with enthesitis-related arthritis. Rheumatology (Oxford, England). 2018;57(12):2167–71.

    Article  Google Scholar 

Download references

Acknowledgements

This research was supported [in part] by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Children’s National Hospital, George Washington University School of Medicine, 111 Michigan Avenue NW, Washington, DC, 20010, USA

    Hemalatha Srinivasalu

  2. Division of Rheumatology, Department of Pediatrics, University of Utah School of Medicine, 81 N Mario Capecchi Drive, 4th Floor, Salt Lake City, UT, 84113, USA

    Erin Brennan Treemarcki

  3. Division of Rheumatology, Children’s National Hospital and National Institute of Arthritis and Musculoskeletal and Skin Diseases, Building 10 10N-311, 9000 Rockville Pike, Bethesda, MD, 20892, USA

    Christopher Redmond

Authors
  1. Hemalatha Srinivasalu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin Brennan Treemarcki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher Redmond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hemalatha Srinivasalu.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Spondyloarthritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Srinivasalu, H., Treemarcki, E.B. & Redmond, C. Advances in Juvenile Spondyloarthritis. Curr Rheumatol Rep 23, 70 (2021). https://doi.org/10.1007/s11926-021-01036-4

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11926-021-01036-4

Keywords

Search

Navigation